AIMS: To demonstrate that pregnancy-related complications are associated with alterations in cardiovascular and cerebrovascular microRNA expression. Gene expression of 32 microRNAs (miR-1-3p, miR-16-5p, miR-17-5p, miR-20a-5p, miR-20b-5p, miR-21-5p, miR-23a-3p, miR-24-3p, miR-26a-5p, miR-29a-3p, miR-33a-5p, miR-92a-3p, miR-100-5p, miR-103a-3p, miR-122-5p, miR-125b-5p, miR-126-3p, miR-130b-3p, miR-133a-3p, miR-143-3p, miR-145-5p, miR-146a-5p, miR-155-5p, miR-181a-5p, miR-195-5p, miR-199a-5p, miR-208a-3p, miR-210-3p, miR-221-3p, miR-342-3p, miR-499a-5p, and miR-574-3p) was assessed in placental tissues, compared between groups (35 gestational hypertension, 80 preeclampsia, 35 intrauterine growth restriction and 20 normal pregnancies) and correlated with the severity of the disease with respect to clinical signs, delivery date, and Doppler ultrasound parameters. Initially, selection and validation of endogenous controls for microRNA expression studies in placental tissues affected by pregnancy-related complications have been carried out. RESULTS: The expression profile of microRNAs was different between pregnancy-related complications and controls. The up-regulation of miR-499a-5p was a common phenomenon shared between gestational hypertension, preeclampsia, and intrauterine growth restriction. Preeclamptic pregnancies delivering after 34 weeks of gestation and IUGR with abnormal values of flow rate in the umbilical artery demonstrated up-regulation of miR-1-3b. Preeclampsia and IUGR requiring termination of gestation before 34 weeks of gestation were associated with down-regulation of miR-26a-5p, miR-103a-3p and miR-145-5p. On the other hand, some of microRNAs (miR-16-5p, miR-100-5p, miR-122-5p, miR-125b-5p, miR-126-3p, miR-143-3p, miR-195-5p, miR-199a-5p, miR-221-3p, miR-342-3p, and miR-574-3p) were only down-regulated or showed a trend to down-regulation just in intrauterine growth restriction pregnancies requiring the delivery before 34 weeks of gestation. CONCLUSION: Epigenetic changes induced by pregnancy-related complications in placental tissue may cause later onset of cardiovascular and cerebrovascular diseases in offspring.

Department of Molecular Biology and Cell Pathology 3rd Faculty of Medicine Charles University Prague Czech Republic

Department of Molecular Biology and Cell Pathology 3rd Faculty of Medicine Charles University Prague Czech Republic; Institute for the Care of the Mother and Child 3rd Faculty of Medicine Charles University Prague Czech Republic

Institute for the Care of the Mother and Child 3rd Faculty of Medicine Charles University Prague Czech Republic

Zobrazit více v PubMed

WHO. Geographic variation in the incidence of hypertension in pregnancy. World Health Organization International Collaborative Study of Hypertensive Disorders of Pregnancy. Am J Obstet Gynecol. 1988;158(1): 80–83. PubMed

Bamfo JE, Odibo AO. Diagnosis and management of fetal growth restriction. J Pregnancy. 2011; 640715 10.1155/2011/640715 PubMed DOI PMC

ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Obstet Gynecol. 2002; 99(1): 159–167. PubMed

Khong TY, De Wolf F, Robertson WB, Brosens I. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol. 1986;93(10): 1049–1059. PubMed

Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006;367(9516): 1066–1074. PubMed

Miko E, Meggyes M, Bogar B, Schmitz N, Barakonyi A, Varnagy A, et al. Involvement of Galectin-9/TIM-3 pathway in the systemic inflammatory response in early-onset preeclampsia. PLoS One. 2013;8(8): e71811 10.1371/journal.pone.0071811 PubMed DOI PMC

Garovic VD, Hayman SR. Hypertension in pregnancy: an emerging risk factor for cardiovascular disease. Nat Clin Pract Nephrol. 2007;3(11): 613–622. PubMed

Libby G, Murphy DJ, McEwan NF, Greene SA, Forsyth JS, Chien PW, et al. Pre-eclampsia and the later development of type 2 diabetes in mothers and their children: an intergenerational study from the Walker cohort. Diabetologia. 2007;50(3): 523–530. PubMed

Männistö T, Mendola P, Vääräsmäki M, Järvelin MR, Hartikainen AL, Pouta A, et al. Elevated blood pressure in pregnancy and subsequent chronic disease risk. Circulation. 2013;127(6): 681–690. 10.1161/CIRCULATIONAHA.112.128751 PubMed DOI PMC

Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007;335(7627):974 PubMed PMC

Craici IM, Wagner SJ, Hayman SR, Garovic VD. Pre-eclamptic pregnancies: an opportunity to identify women at risk for future cardiovascular disease. Womens Health (Lond Engl). 2008;4(2): 133–135. PubMed

Haukkamaa L, Moilanen L, Kattainen A, Luoto R, Kahonen M, Leinonen M, et al. Pre-eclampsia is a risk factor of carotid artery atherosclerosis. Cerebrovasc Dis. 2009;27(6): 599–607. 10.1159/000216834 PubMed DOI

Lykke JA, Langhoff-Roos J, Sibai BM, Funai EF, Triche EW, Paidas MJ. Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother. Hypertension. 2009;53(6): 944–951. 10.1161/HYPERTENSIONAHA.109.130765 PubMed DOI

Berks D, Hoedjes M, Raat H, Duvekot JJ, Steegers EA, Habbema JD. Risk of cardiovascular disease after pre-eclampsia and the effect of lifestyle interventions: a literature-based study. BJOG. 2013;120(8): 924–931. 10.1111/1471-0528.12191 PubMed DOI

McDonald SD, Ray J, Teo K, Jung H, Salehian O, Yusuf S, et al. Measures of cardiovascular risk and subclinical atherosclerosis in a cohort of women with a remote history of preeclampsia. Atherosclerosis. 2013;229(1): 234–239. 10.1016/j.atherosclerosis.2013.04.020 PubMed DOI

Borna S, Neamatipoor E, Radman N. Risk of coronary artery disease in women with history of pregnancies complicated by preeclampsia and LBW. J Matern Fetal Neonatal Med. 2012;25(7): 1114–1116. 10.3109/14767058.2011.624218 PubMed DOI

Davis EF, Lazdam M, Lewandowski AJ, Worton SA, Kelly B, Kenworthy Y, et al. Cardiovascular risk factors in children and young adults born to preeclamptic pregnancies: a systematic review. Pediatrics. 2012;129(6): e1552–1561. 10.1542/peds.2011-3093 PubMed DOI

Tappia PS, Gabriel CA. Role of nutrition in the development of the fetal cardiovascular system. Expert Rev Cardiovasc Ther. 2006;4(2): 211–225. PubMed

Esplin MS, Fausett MB, Fraser A, Kerber R, Mineau G, Carrillo J, et al. Paternal and maternal components of the predisposition to preeclampsia. N Engl J Med. 2001;344(12): 867–872. PubMed

Skjaerven R, Vatten LJ, Wilcox AJ, Rønning T, Irgens LM, Lie RT. Recurrence of pre-eclampsia across generations: exploring fetal and maternal genetic components in a population based cohort. BMJ. 2005;331(7521): 877 PubMed PMC

Anderson CM. Preeclampsia: exposing future cardiovascular risk in mothers and their children. J Obstet Gynecol Neonatal Nurs. 2007;36(1): 3–8. PubMed

Lai EC. Micro RNAs are complementary to 3' UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet. 2002;30(4): 363–364. PubMed

Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2): 281–297. PubMed

Calin GA, Croce CM. MicroRNAs and chromosomal abnormalities in cancer cells. Oncogene. 2005;25(46): 6202–6210. PubMed

Rosenfeld N, Aharonov R, Meiri E, Rosenwald S, Spector Y, Zepeniuk M, et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol. 2008;26(4): 462–469. 10.1038/nbt1392 PubMed DOI

Pineles BL, Romero R, Montenegro D, Tarca AL, Han YM, Kim YM, et al. Distinct subsets of microRNAs are expressed differentially in the human placentas of patients with preeclampsia. Am J Obstet Gynecol. 2007;196(3): 261.e261–266. PubMed

Hu Y, Li P, Hao S, Liu L, Zhao J, Hou Y. Differential expression of microRNAs in the placentae of Chinese patients with severe pre-eclampsia. Clin Chem Lab Med. 2009;47(8): 923–929. 10.1515/CCLM.2009.228 PubMed DOI

Zhu XM, Han T, Sargent IL, Yin GW, Yao YQ. Differential expression profile of microRNAs in human placentas from preeclamptic pregnancies vs normal pregnancies. Am J Obstet Gynecol. 2009;200(6): 661.e661–667. PubMed

Enquobahrie DA, Abetew DF, Sorensen TK, Willoughby D, Chidambaram K, Williams MA. Placental microRNA expression in pregnancies complicated by preeclampsia. Am J Obstet Gynecol. 2011;204(2): 178.e112–121. PubMed PMC

Maccani MA, Padbury JF, Marsit CJ. miR-16 and miR-21 expression in the placenta is associated with fetal growth. PLoS One. 2011;6(6): e21210 10.1371/journal.pone.0021210 PubMed DOI PMC

Mayor-Lynn K, Toloubeydokhti T, Cruz AC, Chegini N. Expression profile of microRNAs and mRNAs in human placentas from pregnancies complicated by preeclampsia and preterm labor. Reprod Sci. 2011;18(1): 46–56. 10.1177/1933719110374115 PubMed DOI PMC

Noack F, Ribbat-Idel J, Thorns C, Chiriac A, Axt-Fliedner R, Diedrich K, et al. miRNA expression profiling in formalin-fixed and paraffin-embedded placental tissue samples from pregnancies with severe preeclampsia. J Perinat Med. 2011;39(3): 267–271. 10.1515/JPM.2011.012 PubMed DOI

Bai Y, Yang W, Yang HX, Liao Q, Ye G, Fu G, et al. Downregulated miR-195 detected in preeclamptic placenta affects trophoblast cell invasion via modulating ActRIIA expression. PLoS One. 2012;7(6): e38875 10.1371/journal.pone.0038875 PubMed DOI PMC

Ishibashi O, Ohkuchi A, Ali MM, Kurashina R, Luo SS, Ishikawa T, et al. Hydroxysteroid (17-β) dehydrogenase 1 is dysregulated by miR-210 and miR-518c that are aberrantly expressed in preeclamptic placentas: a novel marker for predicting preeclampsia. Hypertension. 2012;59(2): 265–273. 10.1161/HYPERTENSIONAHA.111.180232 PubMed DOI

Muralimanoharan S, Maloyan A, Mele J, Guo C, Myatt LG, Myatt L. MIR-210 modulates mitochondrial respiration in placenta with preeclampsia. Placenta. 2012;33(10): 816–823. 10.1016/j.placenta.2012.07.002 PubMed DOI PMC

Wang W, Feng L, Zhang H, Hachy S, Satohisa S, Laurent LC, et al. Preeclampsia up-regulates angiogenesis-associated microRNA (i.e., miR-17, -20a, and -20b) that target ephrin-B2 and EPHB4 in human placenta. J Clin Endocrinol Metab. 2012;97(6): E1051–9. 10.1210/jc.2011-3131 PubMed DOI PMC

Higashijima A, Miura K, Mishima H, Kinoshita A, Jo O, Abe S, et al. Characterization of placenta-specific microRNAs in fetal growth restriction pregnancy. Prenat Diagn. 2013;33(3): 214–222. 10.1002/pd.4045 PubMed DOI

Choi SY, Yun J, Lee OJ, Han HS, Yeo MK, Lee MA, et al. MicroRNA expression profiles in placenta with severe preeclampsia using a PNA-based microarray. Placenta. 2013;34(9): 799–804. 10.1016/j.placenta.2013.06.006 PubMed DOI

Yan T, Liu Y, Cui K, Hu B, Wang F, Zou L. MicroRNA-126 regulates EPCs function: implications for a role of miR-126 in preeclampsia. J Cell Biochem. 2013;114(9): 2148–2159. 10.1002/jcb.24563 PubMed DOI

Hong F, Li Y, Xu Y. Decreased placental miR-126 expression and vascular endothelial growth factor levels in patients with pre-eclampsia. J Int Med Res. 2014;42(6): 1243–1251. 10.1177/0300060514540627 PubMed DOI

Li X, Li C, Dong X, Gou W. MicroRNA-155 inhibits migration of trophoblast cells and contributes to the pathogenesis of severe preeclampsia by regulating endothelial nitric oxide synthase. Mol Med Rep. 2014;10(1): 550–554. 10.3892/mmr.2014.2214 PubMed DOI

Luo R, Shao X, Xu P, Liu Y, Wang Y, Zhao Y, et al. MicroRNA-210 contributes to preeclampsia by downregulating potassium channel modulatory factor 1. Hypertension. 2014;64(4): 839–845. 10.1161/HYPERTENSIONAHA.114.03530 PubMed DOI

Wang Y, Zhang Y, Wang H, Wang J, Zhang Y, Wang Y, et al. Aberrantly up-regulated miR-20a in pre-eclampsic placenta compromised the proliferative and invasive behaviors of trophoblast cells by targeting forkhead box protein A1. Int J Biol Sci. 2014;10(9): 973–982. 10.7150/ijbs.9088 PubMed DOI PMC

Xu P, Zhao Y, Liu M, Wang Y, Wang H, Li YX, et al. Variations of microRNAs in human placentas and plasma from preeclamptic pregnancy. Hypertension. 2014;63(6): 1276–1284. 10.1161/HYPERTENSIONAHA.113.02647 PubMed DOI

Yang S, Li H, Ge Q, Guo L, Chen F. Deregulated microRNA species in the plasma and placenta of patients with preeclampsia. Mol Med Rep. 2015;12(1): 527–534. 10.3892/mmr.2015.3414 PubMed DOI

He A, Zhu L, Gupta N, Chang Y, Fang F. Overexpression of micro ribonucleic acid 29, highly up-regulated in diabetic rats, leads to insulin resistance in 3T3-L1 adipocytes. Mol Endocrinol. 2007;21: 2785–2794. PubMed

Elmén J, Lindow M, Silahtaroglu A, Bak M, Christensen M, Lind-Thomsen A, et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res. 2008;36(4): 1153–1162. PubMed PMC

Elmén J, Lindow M, Schütz S, Lawrence M, Petri A, Obad S, et al. LNA-mediated microRNA silencing in non-human primates. Nature. 2008;452(7189): 896–899. 10.1038/nature06783 PubMed DOI

Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell. 2008;15: 272–284. 10.1016/j.devcel.2008.07.008 PubMed DOI PMC

Wang S, Aurora AB, Johnson BA, Qi X, McAnallz J, Hill JA, et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell. 2008;15: 261–271. 10.1016/j.devcel.2008.07.002 PubMed DOI PMC

Chen T, Huang Z, Wang L, Wang Y, Wu F, Meng S, et al. MicroRNA-125a-5p partly regulates the inflammatory response, lipid uptake, and ORP9 expression in oxLDL-stimulated monocytes/macrophages. Cardiovasc Res. 2009;83: 131–139. 10.1093/cvr/cvp121 PubMed DOI

Marquart TJ, Allen RM, Ory DS, Baldan A. miR-33 links SREBP-2 induction to repression of sterol transporters. Proc Natl Acad Sci U.S.A. 2010;107: 12228–12232. 10.1073/pnas.1005191107 PubMed DOI PMC

Najafi-Shoushtari SH, Kristo F, Li Y, Shioda T, Cohen DE, Gerszten RE, et al. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science. 2010;328: 1566–1569 10.1126/science.1189123 PubMed DOI PMC

Rayner KJ, Suarez Y, Davalos A, Parathath S, Fitzgerald ML, Tamehiro N, et al. Mir-33 contributes to the regulation of cholesterol homeostasis. Science. 2010;328: 1570–1573. 10.1126/science.1189862 PubMed DOI PMC

Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, Prokopi M, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res. 2010;107(6): 810–817. 10.1161/CIRCRESAHA.110.226357 PubMed DOI

Zhao H, Guan J, Lee HM, Sui Y, He L, Siu JJ, et al. Up-regulated pancreatic tissue microRNA-375 associates with human type 2 diabetes through β-cell deficit and islet amyloid deposition. Pancreas. 2010;39: 843–846. 10.1097/MPA.0b013e3181d12613 PubMed DOI

Kida K, Nakajima M, Mohri T, Oda Y, Takagi S, Fukami T, et al. PPARα is regulated by miR-21 and miR-27b in human liver. Pharm Res. 2011;28: 2467–2476. 10.1007/s11095-011-0473-y PubMed DOI

Pullen TJ, da Silva Xavier G, Kelsey G, Rutter GA. miR-29a and miR-29b contribute to pancreatic β-cell-specific silencing of monocarboxylate transporter 1 (Mct1). Mol Cell Biol. 2011;31: 3182–3194. 10.1128/MCB.01433-10 PubMed DOI PMC

Rayner KJ, Esau CC, Hussain FN, McDaniel AL, Marshall SM, van Gils JM, et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature. 2011;478(7369): 404–407. 10.1038/nature10486 PubMed DOI PMC

Ryu HS, Park SY, Ma D, Zhang J, Lee W. The induction of microRNA targeting IRS-1 is involved in the development of insulin resistance under conditions of mitochondrial dysfunction in hepatocytes. PLoS ONE. 2011;6: e17343 10.1371/journal.pone.0017343 PubMed DOI PMC

Yang K, He YS, Wang XQ, Lu L, Chen QJ, Liu J, et al. Mir-146a inhibits oxidized low-density lipoprotein-induced lipid accumulation and inflammatory response via targeting Toll-like receptor 4. FEBS Lett. 2011;585: 854–860. 10.1016/j.febslet.2011.02.009 PubMed DOI

Zhong D, Zhang Y, Zeng YJ, Gao M, Wu GZ, Hu CJ, et al. MicroRNA-613 represses lipogenesis in HepG2 cells by downregulating LXRα. Lipids Health Dis. 2013;12: 32 10.1186/1476-511X-12-32 PubMed DOI PMC

Zhong D, Huang G, Zhang Y, Zeng Y, Xu Z, Zhao Y, et al. MicroRNA-1 and microRNA-206 suppress LXRα-induced lipogenesis in hepatocytes. Cell Signaling. 2013;25: 1429–1437. PubMed

van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN. Control of stress-dependent cardiac growth and gene expression bz a microRNA. Science. 2007;316: 575–579. PubMed

Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008;456(7224): 980–984. 10.1038/nature07511 PubMed DOI

Callis TE, Pandya K, Seok HY, Tang RH, Tatsuguchi M, Huang ZP, et al. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest. 2009;119(9): 2772–2786. 10.1172/JCI36154 PubMed DOI PMC

Elia L, Quintavalle M, Zhang J, Contu R, Cossu L, Latronico MV, et al. The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease. Cell Death Differ. 2009;16(12): 1590–1598. 10.1038/cdd.2009.153 PubMed DOI PMC

Xin M, Small EM, Sutherland LB, Qi X, McAnally J, Plato CF, et al. MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells Indry. Gens Dev. 2009;23: 2166–2178. PubMed PMC

Li S, Zhu J, Zhang W, Chen Y, Zhang K, Popescu LM. Signature microRNA expression profile of essential hypertension and its novel link to human cytomegalovirus infection. Circulation. 2011;124(2): 175–184. 10.1161/CIRCULATIONAHA.110.012237 PubMed DOI

Norata GD, Pinna C, Yappella F, ELia L, Sala A, Condorelli G, et al. (2012) MicroRNA 143–145 deficiency impairs vascular function. Int J Immunopathol Pharmacol. 2012;25: 467–474. PubMed

O´Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D. MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci U.S.A. 2007;104: 1604–1609. PubMed PMC

Harris TA, Yamakuchi M, Ferlito M, Mendell JT, Lowenstein CJ. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci U.S.A. 2008;105: 1516–1521. 10.1073/pnas.0707493105 PubMed DOI PMC

Wang YS, Wang HY, Liao YC, Tsai PC, Chen KC, Cheng HY, et al. MicroRNA-195 regulates vascular smooth muscle cell phenotype and prevents neointimal formation. Cardiovasc Res. 2012;95: 517–526. 10.1093/cvr/cvs223 PubMed DOI

Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, Prokopi M, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res. 2010;107(6): 810–817. 10.1161/CIRCRESAHA.110.226357 PubMed DOI

Kong L, Zhu J, Han W, Jiang X, Xu M, Zhao Y, et al. Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study. Acta Diabetol. 2011;48(1): 61–69. 10.1007/s00592-010-0226-0 PubMed DOI

Ji R, Cheng Y, Yue J, Yang J, Liu X, Chen H, et al. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of microRNA in vascular neointimal lesion formation. Circ Res. 2007;100: 1579–1588. PubMed

Hartus TA, Yamakuchi M, Ferlito M, Mendell JT, Lowenstein CJ.MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci U.S.A. 2008;105: 1516–1521. 10.1073/pnas.0707493105 PubMed DOI PMC

Cordes KR, Sheehy NT, White MP, Berry EC, Morton SU, Muth AN, et al. miR-145 and miR-143 regulate smooth Musile cell fate and plasticity. Nature. 2009;460: 705–710. 10.1038/nature08195 PubMed DOI PMC

Raitoharju E, Lyytikäinen LP, Levula M, Oksala N, Mennander A, Tarkka M, et al. miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques in the Tampere Vascular Study. Atherosclerosis. 2011;219(1): 211–217. 10.1016/j.atherosclerosis.2011.07.020 PubMed DOI

Rayner KJ, Moore KJ. The plaque “micro” environment: microRNAs control the risk and the development of atherosclerosis. Curr Atheroscler Rep. 2012;14: 413–421. 10.1007/s11883-012-0272-x PubMed DOI PMC

Yhu J, Chen T, Yang L, Li Z, Wong MM, Zheng X, et al. Regulation of microRNA-155 in atherosclerotic inflammatory responses by targeting MAP3K10. PLoS ONE. 2012;7: e46551 10.1371/journal.pone.0046551 PubMed DOI PMC

Wei Y, Nazari-Jahantigh M, Neth P, Weber C, Schober A. MicroRNA-126, -145, and -155: a therapeutic triad in atherosclerosis? Arterioscler Thromb Vasc Biol. 2013;33: 449–454. 10.1161/ATVBAHA.112.300279 PubMed DOI

Poliseno L, Tuccoli A, Mariani L, Evangelista M, Citti L, Woods K, et al. MicroRNAs modulace the angiogenic properties of HUVECs. Blood. 2006;108: 3068–3071. PubMed

Doebele C, Bonauer A, Fischer A, Scholz A, Reiss Y, Urbich C, et al. Members of the microRNA-17-92 cluster exhibit a cell-intrinsic antiangiogenic function in endothelial cells. Blood. 2010;115(23): 4944–4950. 10.1182/blood-2010-01-264812 PubMed DOI

Grundmann S, Hans FP, Kinniry S, Heinke J, Helbing T, Bluhm F, et al. MicroRNA-100 regulates neovascularization by suppression of mammalian target of rapamycin in endothelial and vascular smooth muscle cells. Circulation. 2011;123(9): 999–1009. 10.1161/CIRCULATIONAHA.110.000323 PubMed DOI

Cheng Y, Liu X, Yang J, Lin Y, Xu DZ, Lu Q, et al. MicroRNA-145, a novel smooth muscle cell phenotzpic marker and modulátor, controls vascular neointimal lesion formation. Circ Res. 2009;105: 158–166. 10.1161/CIRCRESAHA.109.197517 PubMed DOI PMC

Xin M, Small EM, Sutherland LB, Qi X, McAnally J, Plato CF, et al. MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells Indry. Gens Dev. 2009;23: 2166–2178. PubMed PMC

Zernecke A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, Denecke B, et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal. 2009;2(100): ra81 10.1126/scisignal.2000610 PubMed DOI

Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C, et al. Circulating microRNAs in patients with coronary artery disease. Circ Res. 2010;107(5): 677–684. 10.1161/CIRCRESAHA.109.215566 PubMed DOI

Liu X, Cheng Y, Yang J, Xu L, Zhang C. Cell-specific effects of miR-221/222 in vessels: molecular mechanism and therapeutic application. J Mol Cell Cardiol. 2012;52: 245–255. 10.1016/j.yjmcc.2011.11.008 PubMed DOI PMC

Wang YS, Wang HY, Liao YC, Tsai PC, Chen KC, Cheng HY, et al. MicroRNA-195 regulates vascular smooth muscle cell phenotype and prevents neointimal formation. Cardiovasc Res. 2012;95: 517–526. 10.1093/cvr/cvs223 PubMed DOI

Olson EN, Williams RS. Calcineurin signaling and muscle remodeling. Cell. 2000;101: 689–692. PubMed

van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD, et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart silure. Proc Natl Acad Sci U.S.A. 2006;103: 18255–18260. PubMed PMC

Ikeda S, Kong SW, Lu J, Bisping E, Zhang H, Allen PD, et al. Altered microRNA expression in human heart disease. Physiol Genomics. 2007;31(3): 367–373. PubMed

Liu N, Williams AH, Kim Y, McAnally J, Bezprozvannaya S, Sutherland LB, et al. An intragenic MEF2-dependent enhancer directs muscle-specific expression of microRNAs 1 and 133. Proc Natl Acad Sci U.S.A. 2007;104: 20844–20849. PubMed PMC

Tatsuguchi M, Seok HY, Callis TE, Thomson JM, Chen JF, Newman M, et al. Expression of microRNAs is dramatically regulated during cardiomyocyte hypertrophy. J Mol Cell Cardiol. 2007;42: 1137–1141. PubMed PMC

Sucharov C, Bristow MR, Port JD. miRNA expression in the failing human heart: functional correlates. J Mol Cell Cardiol. 2008;45(2): 185–192. 10.1016/j.yjmcc.2008.04.014 PubMed DOI PMC

Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008;456(7224): 980–984. 10.1038/nature07511 PubMed DOI

Urbich C, Kuehbacher A, Dimmeler S. Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc Res. 2008;79: 581–588. 10.1093/cvr/cvn156 PubMed DOI

van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS, et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U.S.A. 2008;105: 13027–13032. 10.1073/pnas.0805038105 PubMed DOI PMC

van Rooij E, Marshall WS, Olson EN. Toward microRNA-based therapeutics for heart disease: the sense in antisepse. Circ Res. 2008;103: 919–928. 10.1161/CIRCRESAHA.108.183426 PubMed DOI PMC

Catalucci D, Gallo P, Condorelli G. MicroRNAs in cardiovascular biology and heart disease. Circ Cardiovasc Genet. 2009;2: 402–408. 10.1161/CIRCGENETICS.109.857425 PubMed DOI

Ikeda S, He A, Kong SW, Lu J, Bejar R, Bodyak N, et al. MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Mol Cell Biol. 2009;29(8): 2193–2204. 10.1128/MCB.01222-08 PubMed DOI PMC

Ji X, Takahashi R, Hiura Y, Hirokawa G, Fukushima Y, Iwai N. Plasma miR-208 as a biomarker of myocardial Indry. Clin Chem. 2009;55: 1944–1949. 10.1373/clinchem.2009.125310 PubMed DOI

Lin Z, Murtaza I, Wang K, Jiao J, Gao J, Li PF. miR-23a functions downstream of NFATc3 to regulace cardiac hypertrophy. Proc Natl Acad Sci U.S.A. 2009;106: 12103–12108. 10.1073/pnas.0811371106 PubMed DOI PMC

Rane S, He M, Sayed D, Vashistha H, Malhotra A, Sadoshima J, et al. Downregulation of miR-199a derepresses hypoxia-inducible factor-1alpha and Sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes. Circ Res. 2009;104(7): 879–886. 10.1161/CIRCRESAHA.108.193102 PubMed DOI PMC

Roy S, Khanna S, Hussain SR, Biswas S, Azad A, Rink C, et al. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc Res. 2009;82: 21–29. 10.1093/cvr/cvp015 PubMed DOI PMC

Adachi T, Nakanishi M, Otsuka Z, Nishimura K, Hirokawa G, Goto Y, et al. Plasma microRNA 499 as a biomarker of acute myocardial infarction. Clin Chem. 2010;56: 1183–1185. 10.1373/clinchem.2010.144121 PubMed DOI

Ai J, Zhang R, Li Y, Pu J, Lu Y, Jiao J, et al. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem Biophys Res Commun. 2010;391(1): 73–77. 10.1016/j.bbrc.2009.11.005 PubMed DOI

Cheng Y, Tan N, Yang J, Liu X, Cao X, He P, et al. A translational study of circulating cell-free microRNA-1 in acute myocardial infarction. Clin Sci. 2010;119: 87–95. 10.1042/CS20090645 PubMed DOI PMC

Corsten MF, Dennert R, Jochems S, Kuznetsova T, Devaux Y, Hofstra L, et al. Circulating microRNA-208b and microRNA-499 reflect myocardial damage in cardiovascular dinase. Circ Cardiovasc Genet. 2010;3: 499–506. 10.1161/CIRCGENETICS.110.957415 PubMed DOI

D'Alessandra Y, Devanna P, Limana F, Straino S, Di Carlo A, Brambilla PG, et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J. 2010;31(22): 2765–2773. 10.1093/eurheartj/ehq167 PubMed DOI PMC

Fukushima Y, Nakanishi M, Nonogi H, Goto Y, Iwai N. Assessment of plasma Midas in congestive heart silure. Circ J. 2010;75: 336–340. PubMed

Song XW, Li Q, Lin L, Wang XC, Li DF, Wang GK, et al. MicroRNAs are dynamically regulated in hypertrophic hearts, and miR-199a is essential for the maintenance of cell size in cardiomyocytes. J Cell Physiol. 2010;225(2): 437–443. 10.1002/jcp.22217 PubMed DOI

Rane S, He M, Sayed D, Yan L, Vatner D, Abdellatif M. An antagonism between the AKT and beta-adrenergic signaling pathways mediated through their reciprocal effects on miR-199a-5p. Cell Signal. 2010;22: 1054–1062. 10.1016/j.cellsig.2010.02.008 PubMed DOI PMC

Voellenkle C, van Rooij J, Cappuzzello C, Greco S, Arcelli D, Di Vito L, Melillo Get al. MicroRNA signatures in peripheral blood mononuclear cells of chronic heart failure patients. Physiol Genomics. 2010;42(3): 420–426. 10.1152/physiolgenomics.00211.2009 PubMed DOI

Wang GK, Zhu JQ, Zhang JT, Li Q, Li Y, He J, et al. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J. 2010;31: 659–666. 10.1093/eurheartj/ehq013 PubMed DOI

Gidlöf O, Andersson P, van der Pals J, Götberg M, Erlinge D. Cardiospecific microRNA plasma levels correlate with troponin and cardiac function in patients with ST elevation myocardial infarction, are selectively dependent on renal elimination, and can be detected in urine samples. Cardiology. 2011;118: 217–226. 10.1159/000328869 PubMed DOI

Shieh JT, Huang Y, Gilmore J, Srivastava D. Elevated miR-499 levels blunt the cardiac stress response. PLoS ONE. 2011;6: e19481 10.1371/journal.pone.0019481 PubMed DOI PMC

Wang JX, Jiao JQ, Li Q, Long B, Wang K, Liu JP, et al. miR-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin-related protein-1. Nat Med. 2011;17: 71–78. 10.1038/nm.2282 PubMed DOI

Zile MR, Mehurg SM, Arroyo JE, Stroud RE, Desantis SM, Spinale FG. Relationship between the tempoval profile of plasma microRNA and left ventricular remodeling in patients following myocardial infarction. Circ Cardiovasc Genet. 2011; 10.1161/CIRCGENETICS.111.959841 PubMed DOI PMC

Long G, Wang F, Duan Q, Chen F, Yang S, Gong W, et al. Human circulating microRNA-1 and microRNA-126 as potential novel indicators for acute myocardial infarction. Int J Biol Sci. 2012;8: 811–818. 10.7150/ijbs.4439 PubMed DOI PMC

Ellis KL, Cameron VA, Troughton RW, Frampton CM, Ellmers LJ, Richards AM. Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients. Eur J Heart Fail. 2013;15(10): 1138–1147. 10.1093/eurjhf/hft078 PubMed DOI

Wei C, Kim IK, Kumar S, Jayasinghe S, Hong N, Castoldi G, et al. NF-κB mediated miR-26a regulation in cardiac fibrosis. J Cell Physiol. 2013;228(7): 1433–1442. 10.1002/jcp.24296 PubMed DOI

Beaumont J, López B, Hermida N, Schroen B, San José G, Heymans S, et al. microRNA-122 down-regulation may play a role in severe myocardial fibrosis in human aortic stenosis through TGF-β1 up-regulation. Clin Sci. 2014;126(7): 497–506. 10.1042/CS20130538 PubMed DOI

Vyas S, Nicolaides KH, Bower S, Campbell S. (1990) Middle cerebral artery flow velocity waveforms in fetal hypoxaemia. Br J Obstet Gynaecol 1990;97:797–803. PubMed

Cohn HE, Sacks EJ, Heymann MA, Rudolph AM. (1974) Cardiovascular responses to hypoxemia and acidemia in fetal lambs. Am J Obstet Gynecol 1974;120:817–824. PubMed

Livak KJ and Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4): 402–408. PubMed

Vandesomple J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geomeztic averaging of multiple internal control genes. Genom Biol. 2002;3: RESEARCH0034. PubMed PMC

Andersen C.L., Ledet-Jensen J., Ørntoft T. Normalization of real-time quantitative RT-PCR data: a model based variance estimation approach to identify genes suited for normalization—applied to bladder- and colon-cancer data-sets. Cancer Research. 2004. (64): 5245–5250. PubMed

Bergkvist A, Forootan A, Zoric N, Stromborn L, Sjoback R, Kubista M. Choosing a normalization strategy for RT-PCR. GenEx syste, aids in the selection of reference genes for standardizing mRNA measurements. Genet Eng Biotechnol News. 2008;28: 13.

Torres A, Torres K, Wdowiak P, Paszkowski T, Maciejewski R. Selection and validation of endogenous controls for microRNA expression studies in endometrioid endometrial cancer tissues. Gynecol Oncol. 2013;130(3): 588–594. 10.1016/j.ygyno.2013.06.026 PubMed DOI

Dweep H, Sticht C, Pandey P, and Gretz N. miRWalk—database: prediction of possible miRNA binding sites by "walking" the genes of three genomes. J Biomed Inform. 2011;44(5): 839–847. 10.1016/j.jbi.2011.05.002 PubMed DOI

Becker C, Hammerle-Fickinger A, Riedmaier I, Pfaffl MW. mRNA and microRNA quality control for RT-qPCR analysis. Methods. 2010;50(4): 237–243. 10.1016/j.ymeth.2010.01.010 PubMed DOI

Bustin SA. Why the need for qPCR publication guidelines?—The case for MIQE. Methods. 2010;50(4): 217–226. 10.1016/j.ymeth.2009.12.006 PubMed DOI

Meyer SU, Pfaffl MW, Ulbrich SE. Normalization strategies for microRNA profiling experiments: a 'normal' way to a hidden layer of complexity? Biotechnol Lett. 2010;32(12): 1777–1788. 10.1007/s10529-010-0380-z PubMed DOI

Tricarico C, Pinzani P, Bianchi S, Paglierani M, Distante V, Pazzagli M, et al. Quantitative real-time reverse transcription polymerase chain reaction: normalization to rRNA or single housekeeping genes is inappropriate for human tissue biopsies. Anal Biochem 2002;309(2):293–300. PubMed

Bas A, Forsberg G, Hammarström S, Hammarström ML. Utility of the housekeeping genes 18S rRNA, beta-actin and glyceraldehyde-3-phosphate-dehydrogenase for normalization in real-time quantitative reverse transcriptase-polymerase chain reaction analysis of gene expression in human T lymphocytes. Scand J Immunol 2004;59(6):566–73. PubMed

Peltier HJ, Latham GJ. Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA 2008;14(5):844–52. 10.1261/rna.939908 PubMed DOI PMC

Suresh K, Chandrashekara S. Sample size estimation and power analysis for clinical research studies. J Hum Reprod Sci 2012;5(1):7–13. 10.4103/0974-1208.97779 PubMed DOI PMC

Myatt L. Placental adaptive responses and fetal programming. J Physiol 2006;572:25–30. PubMed PMC

Tappia PS, Gabriel CA. Role of nutrition in the development of the fetal cardiovascular system. Expert Rev Cardiovasc Ther 2006;4(2):211–25. PubMed

Anderson CM. Preeclampsia: exposing future cardiovascular risk in mothers and their children. J Obstet Gynecol Neonatal Nurs 2007;36(1):3–8. PubMed

Barker DJ, Osmond C, Golding J, Kuh D, Wadsworth ME. Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. BMJ 1989;298(6673):564–7. PubMed PMC

Barker DJ. The fetal and infant origins of adult disease. BMJ 1990;301(6761):1111 PubMed PMC

Barker DJ, Bagby SP. Developmental antecedents of cardiovascular disease: a historical perspective. J Am Soc Nephrol 2005;16(9):2537–44. PubMed

Hakim J, Senterman MK, Hakim AM. Preeclampsia is a biomarker for vascular disease in both mother and child: the need for a medical alert system. Int J Pediatr 2013;2013:953150 10.1155/2013/953150 PubMed DOI PMC

First Trimester Prediction of Preterm Delivery in the Absence of Other Pregnancy-Related Complications Using Cardiovascular-Disease Associated MicroRNA Biomarkers

Evaluation of Vascular Endothelial Function in Young and Middle-Aged Women with Respect to a History of Pregnancy, Pregnancy-Related Complications, Classical Cardiovascular Risk Factors, and Epigenetics

Postnatal Expression Profile of microRNAs Associated with Cardiovascular and Cerebrovascular Diseases in Children at the Age of 3 to 11 Years in Relation to Previous Occurrence of Pregnancy-Related Complications